Evidence map›Paper›PMID 9486388›Full record

Trial reportClinical and experimental immunology1998

Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group.

T G Evans, T Fitzgerald, D C Gibbons, M C Keefer, H Soucier

3 registry-linked trialsOpen access · greenAbstract readClinical TrialClinical Trial, Phase I
In one paragraph

Trial report in Clinical and experimental immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000632 phase1completednot on this map

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrolled14ConditionsHIV Infections, HIV SeronegativityArmsEnv 2-3
NCT00000795 phase1completednot on this map

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrolled28ConditionsHIV InfectionsArmsHIV-1 Peptide Immunogen, Multivalent
NCT00000972 phase1completednot on this map

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrolled64ConditionsHIV Infections, HIV SeronegativityArmsMTP-PE/MF59, Env 2-3
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

T G EvansDepartment of Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA.
T Fitzgerald
D C Gibbons
M C Keefer
H Soucier
University of Rochester · US

Funding

PHS HHS A-45208
6 · The paper itself

Abstract

The Th1/Th2 profile that follows human vaccination may profoundly influence the subsequent course of disease after infection. However, the ability to detect IL-4 has been limited outside trials of live vaccination. By using methods in which memory effector cells are allowed to antigenically expand by short term culture, followed by low-dose mitogenic stimulation, we have been able to follow the Th1/Th2 profile in HIV-1 volunteers enrolled in two phase I studies of HIV immunogens (a recombinant gp120 and a multivalent, octomeric V3 loop peptide). Antigen-specific interferon-gamma (IFN-gamma) could be detected in primary stimulation, but IL-4 was observed only after antigenic expansion and restimulation. In both of these studies the responses after initial immunizations were dominated by IFN-gamma, with IL-4 appearing only after multiple rounds of immunization, and IL-4 was temporally related to antibody production. Concomitant with the IL-4 production, the amount of supernatant IFN-gamma declined. Antigen-specific IL-10 was not detected in either study. Such techniques, which have been shown to correlate with outcomes in immunotherapy, may prove useful as future surrogates of human vaccine response.

Indexed as

AIDS VaccinesCells, CulturedCulture MediaCytokinesHIV Envelope Protein gp120HumansInfluenza VaccinesLymphocyte ActivationPhenotypeTh1 CellsTh2 CellsVaccinationAIDS VaccinesCulture MediaCytokinesHIV Envelope Protein gp120Influenza Vaccines

Identifiers

PMID9486388
PMCPMC1904920
OpenAlexW2082039273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.